These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 3791248)
1. A simple and accurate new method for cytostatics dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination. Lejeune FJ; Ghanem GE Cancer Res; 1987 Jan; 47(2):639-43. PubMed ID: 3791248 [TBL] [Abstract][Full Text] [Related]
2. [Surgical treatment of malignant melanoma of the limbs combined with thermochemotherapy under extracorporeal circulation]. Truchetet F; Grosshans E; Kretz JG; Bartier JC; Laplanche G Ann Dermatol Venereol; 1988; 115(5):573-85. PubMed ID: 3195954 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of melphalan in isolated perfusion of the limbs. Benckhuijsen C; Varossieau FJ; Hart AA; Wieberdink J; Noordhoek J J Pharmacol Exp Ther; 1986 May; 237(2):583-8. PubMed ID: 3701643 [TBL] [Abstract][Full Text] [Related]
4. Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion. Di Filippo F; Giacomini P; Rossi CR; Santinami M; Anzà M; Garinei R; Perri P; Botti C; Di Angelo P; Sofra C; Pasqualoni R; Sperduti I; Cavaliere F; Di Filippo S; Corrias F; Armenti A; Ferraresi V; Ginebri A In Vivo; 2009; 23(2):347-52. PubMed ID: 19414425 [TBL] [Abstract][Full Text] [Related]
5. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis. Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758 [TBL] [Abstract][Full Text] [Related]
6. Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique. Cattel L; Buffa E; De Simone M; Cesana P; Novello S; Dosio F; Ceruti M Anticancer Res; 2001; 21(3C):2243-8. PubMed ID: 11501854 [TBL] [Abstract][Full Text] [Related]
7. Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs? Klaase JM; Kroon BB; van Geel AN; Eggermont AM; Franklin HR; van Dongen JA Melanoma Res; 1994 Mar; 4 Suppl 1():13-6. PubMed ID: 8038589 [TBL] [Abstract][Full Text] [Related]
9. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Fraker DL; Alexander HR; Andrich M; Rosenberg SA Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465 [TBL] [Abstract][Full Text] [Related]
10. A comparison of dosimetric methods in isolated limb perfusion with melphalan for malignant melanoma of the lower extremity. Byrne DS; McKay AJ; Blackie R; MacKie RM Eur J Cancer; 1996 Nov; 32A(12):2082-7. PubMed ID: 9014749 [TBL] [Abstract][Full Text] [Related]
11. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Kroon HM; Moncrieff M; Kam PC; Thompson JF Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289 [TBL] [Abstract][Full Text] [Related]
12. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345 [TBL] [Abstract][Full Text] [Related]
13. Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system. Zwaveling JH; Maring JK; Mulder AB; Bom VJ; van Ginkel RJ; Schraffordt Koops H; Girbes AR; Hoekstra HJ; van der Meer J Cancer Res; 1996 Sep; 56(17):3948-53. PubMed ID: 8752162 [TBL] [Abstract][Full Text] [Related]
15. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Wieberdink J; Benckhuysen C; Braat RP; van Slooten EA; Olthuis GA Eur J Cancer Clin Oncol; 1982 Oct; 18(10):905-10. PubMed ID: 6891640 [TBL] [Abstract][Full Text] [Related]
16. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836 [TBL] [Abstract][Full Text] [Related]
17. An accurate method for cytostatic dosimetry in isolation perfusion based on limb vascular volume determination. Lejeune FJ; Ghanem GE; Liénard D; Ewalenko P Antibiot Chemother (1971); 1988; 40():63-76. PubMed ID: 3415204 [No Abstract] [Full Text] [Related]
18. [Isolated limb perfusion with tumor necrosis factor for malignancies of the limbs]. Abu-Abid S; Gutman M; Lev D; Inbar M; Chaitchik S; Sorkine P; Rudick V; Meller I; Klausner JM Harefuah; 1996 Oct; 131(7-8):227-32, 296, 295. PubMed ID: 8940515 [TBL] [Abstract][Full Text] [Related]
19. Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma. Hafström L; Hugander A; Jönsson PE; Westling H; Ehrsson H Cancer Treat Rep; 1984 Jun; 68(6):867-72. PubMed ID: 6733699 [TBL] [Abstract][Full Text] [Related]
20. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Thompson JF; Siebert GA; Anissimov YG; Smithers BM; Doubrovsky A; Anderson CD; Roberts MS Br J Cancer; 2001 Jul; 85(2):157-65. PubMed ID: 11461070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]